NASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis $2.56 -0.03 (-1.16%) Closing price 04:00 PM EasternExtended Trading$2.60 +0.04 (+1.45%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rocket Pharmaceuticals Stock (NASDAQ:RCKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rocket Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.53▼$2.6650-Day Range$2.59▼$3.8652-Week Range$2.51▼$5.45Volume1.82 million shsAverage Volume2.53 million shsMarket Capitalization$281.04 millionP/E RatioN/ADividend YieldN/APrice Target$8.63Consensus RatingHold Company Overview Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses lentiviral and adeno-associated virus (AAV) vector platforms to deliver genetic material intended to address the underlying causes of inherited disorders, with research programs spanning hematology, immunology, metabolic disease and cardiac conditions. Rocket’s pipeline has included RP-L102 for Fanconi anemia, a rare inherited bone marrow failure disorder; RP-L201 for leukocyte adhesion deficiency-I, an immune-system disorder; and RP-L301 for pyruvate kinase deficiency, a rare red blood cell disorder. The company has also developed cardiac gene therapy programs, including RP-A501 for Danon disease, a genetic condition that can cause severe cardiomyopathy. Program status and development plans may change as clinical studies and regulatory reviews progress. Rocket Pharmaceuticals was formerly known as InoMed Pharmaceuticals and adopted its current name in 2015. The company is headquartered in Cranbury, New Jersey, and conducts research, clinical development and regulatory activities in collaboration with medical institutions and partners in the United States and other international markets. Its leadership has included Gaurav Shah, M.D., as chief executive officer.AI Generated. May Contain Errors. Read More Rocket Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreRCKT MarketRank™: Rocket Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 549th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingRocket Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 3 sell ratings.Upside PotentialRocket Pharmaceuticals has a consensus price target of $8.63, representing about 240.2% upside from its current price of $2.54.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Rocket Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to decrease in the coming year, from ($1.36) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -14.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -14.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Rocket Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.19% of the float of Rocket Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 0.92%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.83 News SentimentRocket Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rocket Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $432,273.00 in company stock.Percentage Held by Insiders21.30% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rocket Pharmaceuticals' insider trading history. Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCKT Stock News HeadlinesRocket Pharmaceuticals (NASDAQ:RCKT) Shares Break Below Fifty Day Moving Average - Should You Sell?September 29 at 3:32 AM | americanbankingnews.comRocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?September 22, 2026 | insidermonkey.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.October 2 at 1:00 AM | Base Camp Trading (Ad)Chardan Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)September 18, 2026 | theglobeandmail.comMartin Wilson Sells 75,364 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) StockSeptember 16, 2026 | insidertrades.comRocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comRocket Pharma Shares Climb Premarket After FDA Supports Continuation of TrialSeptember 15, 2026 | marketscreener.comMRocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon DiseaseSeptember 15, 2026 | businesswire.comSee More Headlines RCKT Stock Analysis - Frequently Asked Questions How have RCKT shares performed this year? Rocket Pharmaceuticals' stock was trading at $3.51 at the beginning of the year. Since then, RCKT shares have decreased by 27.8% and is now trading at $2.5350. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings data on Monday, August, 10th. The biotechnology company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.86 by $0.22. When did Rocket Pharmaceuticals IPO? Rocket Pharmaceuticals (RCKT) raised $94 million in an IPO on Friday, February 6th 2015. The company issued 6,700,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), Humana (HUM), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/10/2026Today10/02/2026Status update10/06/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 8 days, RCKT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RCKT CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees202Year Founded2018Price Target and Rating Average Price Target for Rocket Pharmaceuticals$8.63 High Price Target$15.00 Low Price Target$3.00 Potential Upside/Downside+236.9%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$223.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.77% Return on Assets-44.92% Debt Debt-to-Equity Ratio0.05 Current Ratio9.24 Quick Ratio9.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book1.00Miscellaneous Outstanding Shares109,780,000Free Float86,393,000Market Cap$281.04 million OptionableOptionable Beta0.50 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:RCKT) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCKT Stock Alerts